Brendan Teehan, Chief Commercial Officer of Pacira BioSciences, Inc., filed a Form 4 on November 17, 2026, disclosing the disposition of common stock and cancellation of a stock option in connection with the company's merger with a Viatris subsidiary.
Key Highlights
- Shares disposed: Teehan disposed of 100,934.268 shares of common stock on November 17, 2026, at a price of $36.50 per share.
- Merger trigger: The disposition was made pursuant to the Agreement and Plan of Merger dated October 8, 2026, among Pacira BioSciences, Viatris Inc., and Peach Purchaser Sub Inc.
- Merger outcome: At the effective time of the merger, each share was converted into the right to receive $36.50, net of applicable withholding taxes and without interest, according to the filing.
- RSU treatment: Outstanding RSUs, whether vested or unvested, were canceled and converted into the right to receive a cash amount equal to the number of shares issuable in settlement multiplied by $36.50, subject to applicable tax withholdings.
- Option canceled: A stock option to purchase 99,500 shares at an exercise price of $26.59, with an expiration date of February 4, 2036, was disposed of on November 17, 2026, leaving zero derivative securities beneficially owned.
- Post-transaction ownership: Following the reported transactions, Teehan's directly held common stock balance is reported as zero shares.
Pacira BioSciences Merger Closes: Teehan's Holdings Converted Under Viatris Deal
According to the filing, Brendan Teehan, Chief Commercial Officer of Pacira BioSciences, Inc. (NASDAQ:PCRX), reported the disposition of 100,934.268 shares of common stock on November 17, 2026, the effective time of the merger. The transaction was made pursuant to the Agreement and Plan of Merger dated October 8, 2026, by and among Pacira BioSciences, Viatris Inc., and Peach Purchaser Sub Inc. Under the merger agreement, Peach Purchaser Sub Inc. consummated a cash tender offer for all outstanding shares at $36.50 per share, net of applicable withholding taxes and without interest, after which it merged with and into Pacira BioSciences, with Pacira continuing as the surviving corporation and a wholly owned subsidiary of Viatris.
The filing notes that the 100,934.268 shares disposed of included 728.896 shares acquired in June 2026 and 267.272 shares acquired in November 2026 under the company's Amended and Restated 2014 Employee Stock Purchase Plan, as well as restricted stock unit awards. At the effective time, each outstanding RSU, whether vested or unvested, was canceled and converted into the right to receive a cash amount equal to the product of the total shares issuable in settlement multiplied by the $36.50 offer price, subject to applicable tax withholdings.
Separately, the filing discloses that a stock option covering 99,500 shares with an exercise price of $26.59 per share and an expiration of February 4, 2036, was also disposed of on November 17, 2026. The filing states that at the effective time, each outstanding option, whether vested or unvested, was canceled and converted into the right to receive cash equal to the excess, if any, of the offer price over the per-share exercise price, multiplied by the number of shares subject to the option, subject to applicable tax withholdings. Any option with a per-share exercise price greater than or equal to the offer price was canceled with no consideration payable. Following all reported transactions, Teehan's directly held beneficial ownership in common stock and derivative securities is reported as zero.
What Was Disclosed
Brendan Teehan, Chief Commercial Officer of Pacira BioSciences, disclosed the disposition of 100,934.268 shares of common stock and the cancellation of a 99,500-share stock option on November 17, 2026, the effective time of the Viatris merger, reducing his directly held beneficial ownership to zero.




Please wait processing your request...